BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

MaxCyte (MXCT)MaxCyteCompany update

ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed

Related news

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MXCTMaxCyte2026-09-11 20:30 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EDITEditas Medicine2026-09-08 11:00 EST

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

SRPTSarepta Therapeutics2026-07-27 12:30 EST

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-09-23 12:00 EST

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

MXCTMaxCyte2026-09-23 12:05 EST

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

MXCTMaxCyte2026-09-11 20:30 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-08-19 12:05 EST

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MXCTMaxCyte2026-08-12 20:05 EST

MaxCyte Reports Second Quarter 2026 Financial Results

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Stock data

Close
1.09 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States